X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

INDIAN JOURNAL OF PHARMACOLOGY

期刊標題檢索 INDIAN J PHARMA 最新評論: None (2023-09-12)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[INDIAN JOURNAL OF PHARMACOLOGY]您好,您是該頁面的第 9265 位訪客。

期刊簡介
期刊名稱INDIAN JOURNAL OF PHARMACOLOGY INDIAN JOURNAL OF PHARMACOLOGY
LetPub Score
4.9
50 ratings
Rate

Reputation
6.4

Influence
3.3

Speed
7.0

期刊簡稱INDIAN J PHARMACOL
ISSN0019-5472
E-ISSN1998-3751
h-indexN.A.
CiteScore
CiteScoreSJRSNIPCiteScore Rank
4.000.3490.478
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Pharmacology (medical)
Q2125 / 272
Category: Medicine
Subcategory: Pharmacology
Q3177 / 313

自引率 (2023-2024)0.00%自引率趨勢
掲載範囲
Indian Journal of Pharmacology accepts, in English, review articles, articles for educational forum, original research articles (full length and short communications), letter to editor, case reports and interesting fillers. Articles concerning all aspects of pharmacology will be considered. Articles of general interest (e.g. methods, therapeutics, medical education, interesting websites, new drug information and commentary on a recent topic) are also welcome.
官方網站 http://www.ijpsonline.com/
在線稿件提交http://www.ijpsonline.com/submit-article.html
開放訪問No
出版商Wolters Kluwer Health
主題領域Pharmacology, Toxicology and Pharmaceutics
出版國/地區India
發行頻率隔月刊行
創刊年1939
每年文章數60每年文章數趨勢
黃金OA百分比0.00%
Web of Science 四分位
2023-2024
WOS Quartile: Q4

CategoryEditionJIF QuartileJIF RankingJIF Percentage
PHARMACOLOGY & PHARMACYSCIEQ4275/354
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0019-5472%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據:
競爭力 *來自作者的數據: 0%
參考鏈接
相關期刊 【INDIAN JOURNAL OF PHARMACOLOGY】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    VaccinesH-index: 0

    CiteScore: 8.90
    Diabetes Metabolic Syndrome and ObesityH-index: 35

    CiteScore: 5.90
    DRUGS IN R&DH-index: 39

    CiteScore: 5.10
    Contemporary Clinical Trials CommunicationsH-index: 0

    CiteScore: 2.70
    BULLETIN OF PHARMACEUTICAL SCIENCESH-index: 0

    CiteScore: 0.40
    Journal of Jilin University Medicine EditionH-index: 0

    CiteScore: 0.20
    Antiviral Chemistry and ChemotherapyH-index: 0

    CiteScore: 5.20
    Current Pharmacogenomics and Personalized MedicineH-index: 0

    CiteScore: 0.40
    Advances in PharmacologyH-index: 0

    CiteScore: 9.10
    Chinese Journal of Cancer BiotherapyH-index: 0

    CiteScore: 0.20
    學科內最受檢索的期刊 頁面查看次數
    Contemporary Clinical Trials Communications243018
    Vaccines49894
    Diabetes Metabolic Syndrome and Obesity36151
    DRUGS IN R&D12549
    BULLETIN OF PHARMACEUTICAL SCIENCES8092
    Current Pharmacogenomics and Personalized Medicine3389
    Biomedical and Pharmacology Journal3222
    Advances in Pharmacology3072
    Infectious Disorders - Drug Targets2304
    Anti-Infective Agents2208
  •  

    INDIAN JOURNAL OF PHARMACOLOGY INDIAN JOURNAL OF PHARMACOLOGY
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [INDIAN JOURNAL OF PHARMACOLOGY] 的評論撰寫評論
作者: 百花菱凡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-12 23:15:53 評論於
None
(0) 讚! | 百花菱凡

作者: 水月淑霞


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-28 22:30:02 評論於
Is there a template for the ethical approval document of this journal?
(0) 讚! | 水月淑霞

作者: 百花菱凡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-16 08:09:41 評論於
The application submitted in September 2022 will be processed in July 2023. If you are not in a hurry, you may receive a pleasant surprise
(0) 讚! | 百花菱凡

作者: Colin Tobias


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-06-15 20:56:38 評論於
It has been 449 days since it was repaired, but they never respond to emails
(0) 讚! | Colin Tobias

作者: Colin Tobias


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-05-14 14:36:45 評論於
Review Speed: 24.0
Emphasis of Research Direction: Pharmacology
Experience of sharing: Very, very slow, it has been 425 days, and there has been no final decision after revision. Emails are never replied to
(0) 讚! | Colin Tobias

作者: 子昂公子


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-19 12:11:18 評論於
I would like to ask how much the layout fee is
(0) 讚! | 子昂公子

作者: 子昂公子


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-19 08:52:25 評論於
I would like to ask how much the layout fee is
(0) 讚! | 子昂公子

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 11:04:34 評論於
Every study is inevitably limited by its research constraints. Factors such as research design and research methods can contribute to these limitations
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 10:56:27 評論於
There is no fixed requirement for paragraphing in the discussion, so feel free to write based on your own situation
(0) 讚! | 维尔娜菲茨杰拉德

作者: 上清雨真


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-26 09:29:18 評論於
What are the limitations of the article?
(0) 讚! | 上清雨真

作者: 龙鳞孝礼


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-25 10:58:52 評論於
How many paragraphs are typically included in a discussion?
(0) 讚! | 龙鳞孝礼

作者: 季雅mm


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-02-24 21:42:08 評論於
Review speed: 24.0 | Submission acceptance rate: 75.0
Experience sharing: Too slow. It took me 461 days from submission to acceptance
(0) 讚! | 季雅mm

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-07-14 10:59:08 評論於
Anyway, it's unlikely that the situation will change, so as long as it doesn't get worse, that's fortunate
(0) 讚! | 凌霄高洁

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2014-07-31 08:51:55 評論於
Wow, this magazine is unbelievably slow. I submitted my article in August last year, it has gone through two rounds of status updates and is still under review. I have followed up twice but still no response. This is so frustrating
(0) 讚! | 凌霄高洁

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2014-01-14 12:58:26 評論於
Review speed: 3.0 | Submission hit rate: 25.0 Experience sharing: The acceptance rate in 2013 was 7%, with few submissions from Chinese authors. The review speed is relatively slow, but the editors are very meticulous. If your article is not too profound but has some innovation, you can consider submitting it. However, if it's urgent, it's not recommended to submit. After submitting my article, it was accepted after 6 months. It has been proofread but not yet published
(0) 讚! | 凌霄高洁

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [INDIAN JOURNAL OF PHARMACOLOGY] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*